Literature DB >> 27216415

Multi-component self-assembled anti-tumor nano-vaccines based on MUC1 glycopeptides.

Z Y Sun1, P G Chen, Y F Liu, B D Zhang, J J Wu, Y X Chen, Y F Zhao, Y M Li.   

Abstract

Novel multi-component self-assembled nano-vaccines containing both Pam3CSK4 and CpG were developed for the first time. These multi-component vaccines could effectively activate the macrophages in vitro and elicit strong antibody immune responses and anti-tumor immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27216415     DOI: 10.1039/c6cc02000c

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  6 in total

1.  Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Authors:  Nitin T Supekar; Vani Lakshminarayanan; Chantelle J Capicciotti; Anju Sirohiwal; Cathy S Madsen; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2017-11-30       Impact factor: 3.164

2.  Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.

Authors:  Mazda Rad-Malekshahi; Marieke F Fransen; Małgorzata Krawczyk; Mercedeh Mansourian; Meriem Bourajjaj; Jian Chen; Ferry Ossendorp; Wim E Hennink; Enrico Mastrobattista; Maryam Amidi
Journal:  Mol Pharm       Date:  2017-01-27       Impact factor: 4.939

Review 3.  Engineering self-assembled materials to study and direct immune function.

Authors:  Lisa H Tostanoski; Christopher M Jewell
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

4.  A Stable Gold Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens.

Authors:  Kevin R Trabbic; Kristopher A Kleski; Joseph J Barchi
Journal:  ACS Bio Med Chem Au       Date:  2021-09-10

5.  Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines.

Authors:  Qi Feng; Xiaoyue Yu; Yixue Wang; Shiyang Li; Yang Yang
Journal:  RSC Adv       Date:  2021-10-15       Impact factor: 3.361

6.  STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation.

Authors:  Bo-Dou Zhang; Jun-Jun Wu; Wen-Hao Li; Hong-Guo Hu; Lang Zhao; Pei-Yang He; Yu-Fen Zhao; Yan-Mei Li
Journal:  Nano Res       Date:  2022-04-18       Impact factor: 10.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.